LA JOLLA, Calif. — You could easily mistake it for a big CD rack. Inside the lab at the California Institute of Biomedical Research, known as Calibr, sits a stacked array of several dozen plastic ...

FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions. Patient ...

In March 2012, the California Institute for Biomedical Research (Calibr), a nonprofit devoted to translating basic science into drug candidates, launched amid much fanfare. Fueling the hype was an ...

AbbVie , a research-based global biopharmaceutical company, and Calibr, a nonprofit drug discovery division of Scripps Research, today announced a collaboration to develop T-cell therapies aimed ...

LA JOLLA, CA— Calibr, a division of Scripps Research focused on the “bench to bedside” development of transformative medicines, today announced encouraging preliminary data from the first nine ...

LA JOLLA, Calif., May 23, 2014 /PRNewswire-USNewswire/ -- The California Institute for Biomedical Research (Calibr) has received a Translation Award from the Wellcome Trust to develop a novel ...

The U.S. Food and Drug Administration has granted Fast Track designation to a novel "switchable" CAR-T cell therapy developed by Calibr, a division of Scripps Research, in a move to accelerate the ...

Peter G. Schultz, the noted chemist and biotech entrepreneur, sure doesn’t think small. His new biomedical research institute in La Jolla, called Calibr, is researching CAR T cell therapy for cancer, ...

Pfizer and the California Institute for Biomedical Research (Calibr), a nonprofit translational research institute, have entered into a global strategic collaboration to develop novel antibody-based ...

Drug manufacturer AbbVie, and a nonprofit drug discovery division of Scripps Research, Calibr, announced earlier this week that they are partnering to develop chimeric antigen receptor (CAR-T) cell ...

AbbVie to maintain exclusive access to Calibr-Skaggs' switchable CAR-T (sCAR-T) platform to develop novel cell therapy candidates against solid tumor targets identified by AbbVie AbbVie also has the ...